Current situation and prospect of breast cancer liquid biopsy
10.3760/cma.j.issn.0529-5815.2018.02.005
- VernacularTitle: 乳腺癌液体活检的现状与前景
- Author:
Bin ZHOU
1
;
Ling XIN
;
Ling XU
;
Jingming YE
;
Yinhua LIU
Author Information
1. Breast Disease Center, Peking University First Hospital, Beijing 100034, China
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
DNA, neoplasm;
Liquid biopsy
- From:
Chinese Journal of Surgery
2018;56(2):106-109
- CountryChina
- Language:Chinese
-
Abstract:
Liquid biopsy is a diagnostic approach by analyzing body fluid samples. Peripheral blood is the most common sample. Urine, saliva, pleural effusion and ascites are also used. Now liquid biopsy is mainly used in the area of neoplasm diagnosis and treatment. Compared with traditional tissue biopsy, liquid biopsy is minimally invasive, convenient to sample and easy to repeat. Liquid biopsy mainly includes circulating tumor cells and circulating tumor DNA (ctDNA) detection. Detection of ctDNA requires sensitive and accurate methods. The progression of next-generation sequencing (NGS) and digital PCR promote the process of studies in ctDNA. In 2016, Nature published the result of whole-genome sequencing study of breast cancer. The study found 1 628 mutations of 93 protein-coding genes which may be driver mutations of breast cancer. The result of this study provided a new platform for breast cancer ctDNA studies. In recent years, there were many studies using ctDNA detection to monitor therapeutic effect and guide treatment. NGS is a promising technique in accessing genetic information and guiding targeted therapy. It must be emphasized that ctDNA detection using NGS is still at research stage. It is important to standardize ctDNA detection technique and perform prospective clinical researches. The time is not ripe for using ctDNA detection to guide large-scale breast cancer clinical practice at present.
